#USA #Marietta #Airway Therapeutics #Joe Todisco #zelpultida alfa

Airway Therapeutics Strengthens Leadership with Joe Todisco Appointment

Airway Therapeutics, Inc., a biopharmaceutical firm specializing in innovative biological therapies for respiratory, inflammatory, and infectious diseases, has recently made a significant addition to its Board of Directors. Joe Todisco, the current President and CEO of CorMedix Inc., will take on this role effective April 13, 2026. This strategic decision is expected to bolster the company's expertise in commercial development and corporate strategy, particularly as it prepares to advance its lead candidate, zelpultida alfa, through the final stages of development.

Expertise and Experience

With over 20 years in leadership roles within the pharmaceutical and biotechnology sectors, Todisco brings a wealth of knowledge in business strategy, corporate development, and entrepreneurship. His track record includes both creating and expanding specialized pharmaceutical businesses, making him a valuable asset for Airway as they move forward with their product line.

Dr. Marc Salzberg, MD, President and CEO of Airway Therapeutics, expressed enthusiasm about Todisco's appointment, noting, "Joe's extensive experience in the commercialization of hospital products will be invaluable as we prepare to potentially launch zelpultida alfa for the treatment of bronchopulmonary dysplasia (BPD), pending approval. His insight will greatly enhance our strategic direction as we continue to grow."

A Promising Future

For Todisco, joining Airway Therapeutics represents an exciting opportunity to contribute to a company at a pivotal moment in its journey. In his own words, he stated, "This marks an important time for the company, and I am thrilled to join the Board of Directors to help shape the development of Airway’s product portfolio and strategic vision. The innovative approach of Airway towards biological therapies, particularly its lead candidate, zelpultida alfa, addresses critical unmet medical needs, including BPD. I look forward to supporting the team in advancing this mission."

Currently, Todisco leads CorMedix Inc. and has previously held several senior positions at Amneal Pharmaceuticals. His experience includes serving as the Chief Commercial Officer of Amneal Specialty and as Senior Vice President of Corporate Development and International Operations. Notably, he co-founded Gemini Laboratories LLC, a specialized pharmaceutical company that was later acquired by Amneal, showcasing his entrepreneurial spirit and capability in building successful enterprises.

Academic Background

Todisco’s educational credentials are impressive, holding a Bachelor’s degree in Economics from Georgetown University and an MBA from Fordham University’s Graduate School of Business. This background, paired with his professional experience, equips him with a sharp insight into the complexities of the pharmaceutical landscape.

About Airway Therapeutics

Founded with the aim of redefining the prevention and treatment of respiratory, inflammatory, and infectious diseases, Airway Therapeutics focuses on advanced clinical-stage biopharmaceuticals. Its leading candidate, zelpultida alfa, is in late-stage clinical trials aiming to prevent BPD in extremely premature infants, a condition that currently lacks approved preventive therapies. Furthermore, zelpultida alfa is being explored for broader applications across various age groups and pathological conditions, demonstrating the company’s commitment to enhancing outcomes for vulnerable patient populations.

For more information about their pivotal work and upcoming products, visit Airway Therapeutics.

Conclusion

As Airway Therapeutics marches toward new heights with Joe Todisco on board, the future looks promising for the company and the patients it aims to serve. The combination of strategic insight and innovative products positions Airway not only to succeed but also to potentially revolutionize the treatment of serious medical conditions that plague many today.